Naringenin study adds another experimental option for EHV-8

A newly published Veterinary Sciences study, “Antiviral Activity of Naringenin Against Equine Alphaherpesvirus Type 8 In Vitro,” adds another candidate compound to the short list of experimental approaches being tested against EHV-8. The study examines naringenin, a plant-derived flavonoid, against a virus that has drawn increasing concern because of its links to respiratory disease, abortion, and neurologic syndromes in equids, especially donkeys. (mdpi.com)

That context matters. EHV-8, formerly known as asinine herpesvirus 3, has moved from being relatively obscure to a more closely watched pathogen over the past several years. Published reports have tied it to abortion in donkeys in China, neurologic disease in donkeys, and abortion cases in horses, including cases initially mistaken for EHV-1. Researchers have also reported substantial herd-level detection in Chinese donkey populations, reinforcing the view that this is not just a sporadic finding. (pubmed.ncbi.nlm.nih.gov)

The new paper’s headline finding is straightforward: naringenin showed antiviral activity against EHV-8 in vitro. While the source abstract provided here is truncated, outside research helps place the study in a larger development pipeline. A related patent filing describing the use of naringenin against EHV-8 says the compound significantly inhibited replication in susceptible cell lines and appeared to act during the viral replication phase rather than by directly inactivating virus particles; that filing also references mouse-model work as part of the broader development effort. Because patent documents are not the same as peer-reviewed clinical evidence, those details should be read as directional rather than definitive. (eureka.patsnap.com)

Naringenin is also not emerging in a vacuum. Over the past two years, multiple groups have published preclinical EHV-8 studies on other compounds and pathways, including rutin, hyperoside, celastrol, blebbistatin, cobalt protoporphyrin, and heme oxygenase-1-related mechanisms. Taken together, those papers suggest an active search for antiviral candidates, but they also underscore the field’s current limitation: most evidence remains in cell culture or mouse models, not in horses or donkeys under field conditions. (pubmed.ncbi.nlm.nih.gov)

I wasn’t able to find independent expert commentary specifically addressing this naringenin paper. What the broader literature does show is consistent concern about the unmet need. A recent review on equine herpesvirus infections notes that EHV infections remain a significant veterinary and economic challenge, and that EHV-8 has become one of the clinically relevant equine herpesviruses affecting both horses and donkeys. Another recent pathology-focused paper emphasized that research on EHV-8 still lags behind work on better-known equine herpesviruses. (mdpi.com)

Why it matters: For veterinarians, this study is best viewed as an early signal, not a practice-changing development. There is still no licensed antiviral or vaccine specifically for EHV-8, and in vitro inhibition does not answer the questions clinicians need most: achievable dosing in equids, tissue penetration, safety, timing of administration, effect on shedding, and whether treatment changes outcomes in respiratory, reproductive, or neurologic disease. Still, the accumulating EHV-8 literature suggests the pathogen deserves more diagnostic attention in equids with compatible signs, particularly in donkey populations and in abortion or neurologic workups where EHV-1 may be assumed first. (mdpi.com)

There’s also a practical surveillance angle. Reports from China and Europe indicate EHV-8 can affect both donkeys and horses, and at least some equine abortion cases were initially misclassified. That raises the possibility that EHV-8 may be underrecognized where testing panels, case definitions, or clinician awareness remain centered on EHV-1 and EHV-4. For veterinary diagnostic labs and equine practitioners, the growing research volume may support broader differential lists when investigating respiratory outbreaks, reproductive losses, or encephalitic disease in equids. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next meaningful step will be whether the naringenin program advances beyond cell culture into reproducible animal-model data, peer-reviewed mechanistic work, and eventually equid-specific studies that clarify dosing, safety, and real-world clinical value. If that progression doesn’t happen, this will likely remain another interesting preclinical EHV-8 signal rather than a tool veterinarians can use. (eureka.patsnap.com)